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ABSTRACT  
In an effort to develop an alternative formulation of combination of paclitaxel (PTX) and embelin (EMB) suitable for parenteral administration, 
PTX-EMB loaded sterically stabilized solid lipid nanoparticles (SLNs) were prepared, characterized and examined for in vitro cytotoxicity. The 
SLNs, comprising glycerol mono stearate (GMS) as a solid lipid core, Brij 35 used as surfactant and PEGylated phospholipid us ed as stabilizer, 
were prepared using a hot homogenization method. Optimized PTX-EMB loaded formulation, the particle sizes of the prepared SLNs were 
around 300 nm, suggesting that they would be suitable as a parenteral formulation. Transmission electron microscopy showed that the SLNs 
were homogeneous and spherical in shape. Entrapment efficiency of paclitaxel and embelin was 92.83 ± 2.2%, 83.25 ± 2.4% respectively. An in 
vitro drug release study were performed in PBS (pH 7.4) for 80 hrs and observed that paclitaxel and embelin released from the PEGylated SLNs 
was 93.91 ± 4.1 % and 75.63 ± 4.37 % respectively. Furthermore, treatment of the MCF-7 breast cancer cell line with PTX-EMB loaded SLNs 
yielded cytotoxicities comparable to PTX solution, PTX-EMB mixture solution and PTX loaded PEGylated SLNs. These results collectively 
suggest that our optimized SLN formulation may have a potential as alternative delivery system for parenteral administration of  paclitaxel and 
embelin. 
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Paclitaxel (PTX) is one of the most commonly used anti-
cancer agent. Its unique mode of action was discovered in 
1979. PTX has a very complex and unusual chemistry. It is 
considered as a very expensive drug because it is mainly 
extracted from the bark of a slow growing Western (Pacific) 
yew tree, and yields are merely about 0.01% of the dry 
weight of bark. On an average approximately 3000 trees 
must be sacrificed in order to obtain 1 kg of PTX and is 
sufficient to treat about 500 patients; present-day protocol 
prescribes about 2 gm of total treatment PTX is a mitotic 
inhibitor used in cancer chemotherapy [1]. The efficacy of 
Embelin with PTX has already been tested on breast cancer 
cell line and found to be more efficient than individuals 
because embelin up-regulate the TNFα induced apoptosis 
and also potentiate the apoptotic effects of paclitaxel [2]. 
Embelia ribes Burm F a medicinal woody climber belongs to 
the Myrsinaceae family. It is also commonly known as false 
black pepper or vidanga. E. ribes is one of the 32 medicinal 
plant species identified by the Medicinal Board, Govt. of 
India, New Delhi. Nikolovska-Coleska et al. reported embelin 
as a fairly potent, non-peptidic, cell-permeable, small-
molecule inhibitor of XIAP and represents a promising lead 
compound for entirely new class of anticancer agents that 
target the BIR3 domain of XIAP [3]. Paclitaxel is a first-line 
drug used in the treatment of various cancers like breast, 
ovarian, lung, head and neck cancers. It works through 
interfering with normal breakdown of microtubules during 
cell division. Most common marketed formulation of 
paclitaxel is available in a vehicle composed of a 50:50 (v/v) 
mixture of Cremophor EL and dehydrated alcohol. 
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Cremophor EL has been reported to cause serious 
hypersensitivity reactions depends upon the carrier system.  
This project was aimed to eliminate the problems with 
existing formulation by encapsulating the combination of 
drugs i.e. Paclitaxel and Embelin in carrier system like 
PEGylated solid lipid nanoparticles. The prepared carrier 
system delivers via i.v. route. PEGylated nanoparticles not 
only remain in circulation for longer, giving them more time 
to accumulate in the tumor by EPR effect, but also take 
longer time to leave the tumor and return to circulation. 
MATERIAL AND METHODS 
Embelin was purchased from Indofine chemical company, 
Inc,USA. Paclitaxel was obtained as gift sample from Mac-
Chem Products (India) Pvt. Ltd., Mumbai. GMS, Brij-35 were 
purchased from central drug house, delhi and DSPE-PEG2000 
were obtained as a gift sample form Lipoid (Germany). MCF-
7 was purchased from NCCS, Pune. MTT (3-(4, 5-
dimethylthazol-2-yl)-2, 5-diphenyl tetrazolium bromide), 6-
coumarin and Annexin V-FITC Apoptosis Detection Kit were 
purchased from Sigma Aldrich, USA. All solvents used in the 
experiment procedure were analytical grade. 
Instrumentation and software 
All UV-Vis spectrophotometric measurements were carried 
out with a Shimadzu 1700 double beam UV-Visible 
spectrophotometer by a fix slit width of 0.1 nm coupled with 
a computer loaded with Shimadzu UV Probe software of 
version 2.31. Each and every spectrum was saved in CSV 
format so as to find out the zero crossing point. 
Simultaneously estimation 
UV-Visible spectrophotometry is usually used in analytical 
laboratories for quantitative and qualitative analyses. The 
concentration of a model is able to be calculated from the 
UV-Visible absorbance in sequence by means of Beer’s law. 
Derivative spectrophotometry is extremely developed 
technique planned for single and mainly multi component 
analysis by converting the standard spectrum to its first, 
second and higher derivative spectrum. In derivative 
spectrophotometry, we include to originate the nil crossing 
points intended for one drug while other drugs should 
demonstrate substantial absorbance. Every the spectra of the 
sample be scanned between 400-200 nm using a 1.0 cm 
quartz cell. The zero order spectra of the three pure drugs 
within their concentration range were saved separately. 
These spectra were derivatized within 1st, 2nd and 3rd order 
derivative and acceptable results were found by using 1rd 
derivative spectra in which number of data points used for 
slope calculation was set as 49. The first derivative spectra 
were recorded at 300 nm and 249.9 nm for embelin and 
paclitaxel respectively. Standard laboratory mixture and 
commercial formulation were scanned, derivatized and 
analyzed at the same wave length as mentioned above. 
Validation: Sample groundwork for validation was given in 
subsequent manner but dilutions were prepared according 
to solvent required for derivative method. The methods were 
validated with respect to linearity, precision, accuracy, limit 
of detection, limit of quantification [4].  
Linearity: Standard stock solutions were prepared by 
dissolving 10 mg of PTX and 10 mg of EMB in 10 ml 
volumetric flasks in 10 mL Methanolic PBS (7.4) and the 
volume was made up with Methanolic PBS (7.4) to get a 
concentration of 1000 μg/mL of PTX and 1000 μg/mL of 
EMB. From this, suitable dilutions were made in methanolic 
PBS (7.4) to get the working standard solutions of 5-21 
μg/mL for PTX and 3-11 μg/mL for EMB. The absorbance of 
the derivatised spectra was measured at 249.9 nm and 300 
nm for PTX and EMB, respectively in derivative method. 
Several aliquots of standard stock solutions were taken in 
different 10 mL volumetric flask and diluted up to mark with 
methanolic PBS (7.4), such that the final linearity 
concentration of PTX and EMB were 5-13 μg/mL and 5-13 
μg/mL in Method. Six replicate analyses were carried out. 
Plot the calibration curve of absorbance Vs respective 
concentration for PTX and EMB. Find out correlation 
coefficient and regression line equations for PTX and EMB. 
Limit of detection (LOD) and limit of quantization (LOQ): 
LOD and LOQ were designed from the data obtained from the 
linearity studies. The slope of the linearity plot was 
determined. For each of the ten replicate determinations of 
same conc. standard deviation (SD) of the responses was 
calculated. From these values, the parameters Limit of 
Detection and Limit of Quantification were determined on 
the basis of standard deviation and slope of the regression 
equation.  
LOD = (3.3 x SD) / Slope  
LOQ = (10 x SD) / Slope 
Preparation of PTX-EMB loaded PEGylated Solid lipid 
nanoparticles (SLNs) 
PTX-EMB loaded PEGylated SLNs were manufactured by hot 
homogenization method reported by Reddy et al. slight 
modification [5]. Lipid and aqueous phase are prepared 
separately. The lipid was melted (100C above the melting 
point of the lipid used), and both drugs (PTX: EMB) are 
lipophilic in nature so both are dissolve in lipid phase to 
obtain a drug-lipid mixture and in aqueous phase surfactant 
was dissolve in water. Both phases are heated up to 70-80°C 
and then aqueous phase was poured into lipid phase at same 
temperature above the melting point of the lipid. This pre-
emulsion was homogenize for 5 min at 8000 rpm, and then 
sonicate immediately subjected to further size reduction by 
using probe sonication up to 4 min. Then the resultant 
solution was refrigerated at 2-3°C for 15 min. The 
concentration of SLNs ingredients and various process 
variables were optimized on the basis of size, shape, zeta 
potential and entrapment efficiency. A brief method of 
preparation of SLNs is depicted by Figure 1. 
 
 
Figure 1: Preparation of SLNs by hot homogenization 
method 
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Physical stability of SLNs 
The physical stability of the SLNs was evaluated by 
examining changes of mean particle size of SLNs during 
storage at 4 and 25°C [6].   
In-vitro drug release 
The release of PTX and EMB from optimized formulations 
was determined using the dialysis tubing technique with 
slight modification as per method reported elsewhere. In 
brief, an accurately measured PTX-EMB loaded PEGylated 
SLNs were suspended in 2 mL of PBS (pH 7.4) and 
transferred into the pre-soaked dialysis membrane (LA393-
10MT, HIMEDIA) tied with one end, then other end was tied 
up and suspended in a conical flask (500 mL) containing 100 
mL PBS (pH 7.4). The whole set was placed in a shaking 
incubator (Daihanlabtech. LSB-1005RE) adjusted to a 
constant speed (100 rpm) and temperature (37ºC). Samples 
were collected at different intervals for 80 h by maintaining 
the sink conditions and assayed spectrophotometrically for 
drug content at 249.9 nm for PTX and at 300 nm for EMB. All 
experiments were carried out in triplicates. 
In-vitro anticancer activity of SLNs by cell line study 
MCF-7 cell line (breast carcinoma) was obtained from 
National Center for Cell Sciences, Pune, India. Cell lines were 
cultured in Dulbecco’s modified eagle medium (DMEM) 
supplemented with 10% (v/v) heat inactivated fetal bovine 
serum. Cells were maintained in 5% CO2 humidified 
incubator at 37ºC [7]. During subculture, cells were detached 
by trypsinization when they reached 80% confluency and 
split (1:4). Growth medium was changed every 3 days. 
Cell uptake study: Cell uptake study of the formulation was 
performed for qualitative estimation of the uptake of 
liposome by the cancer cells. Cell uptake study of drug loaded 
SLNs was performed on MCF 7 cells (breast cancer cell lines) 
according to the procedure reported earlier by Mauro Gigli 
[8]. The cell culture was freshly prepared by sub culturing 
the cells using Dulbecco’s Minimum Essential Medium 
(DMEM). Formulation was incubated with the cells using 6 
well culture plates for 2 hours [9]. Plain cells in media served 
as positive control. Images of control and test sample were 
taken using Fluoroscent Microscope (Olympus, CK X 41). 
Apoptosis Assay: Human breast cancer cell line (MCF-7) 
was treated Annexin V-FITC Apoptosis detection kit. The 
cells were plated in 6 well plate and treated with different 
concentration of PTX: EMB loaded PEGylated SLNs and 
incubated it. Media was removed and washed with PBS pH 
7.4 and re-suspended in annexin binding buffer. 1 μL annexin 
V dye and PI was added and kept in dark for 30 min. Finally 
cells were washed and observed under fluorescent 
microscope using appropriate filters. 
The cells should separate into three groups: live, apoptotic 
and dead. Live cells show only weak annexin V staining of the 
cellular membrane, while apoptotic cells show asignificantly 
higher degree of surface labelling. Dead cells show both 
membrane staining by Annexin V and strong nuclear staining 
from the propidium iodide [10]. 
Cell viability by MTT assay: The 3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide dye reduction assay 
was performed to determine the cytotoxic effect of the 
different ratio of drugs encapsulated SLNs at various 
concentrations. The assay depends on the reduction of MTT 
by mitochondrial dehydrogenase, an enzyme present in the 
mitochondria of viable cells, to a blue formazan product [11]. 
Briefly, the MCF-7 cells were at a concentration 3 × 104 
cells/mL plated onto 96-well flat bottom culture plates with 
various concentrations of formulation. All cultures were 
incubated for 24 hours at 37°C in a humidified incubator. 
After 24 hours of incubation (37°C, 5% CO2 in a humid 
atmosphere), 5μl of MTT (5 mg/mL in DMSO) was added to 
each well, and the plate was incubated for a further four 
hours at 37°C. The resulting formazan was dissolved in 200 
μL dimethyl sulphoxide and absorbance of the solution was 
read at 595 nm using ELISA plate reader (Biorad, Model 680, 
Japan). All determinations were carried out in triplicate. 
Concentrations of SLNs showing 50% reduction in cell 
viability (i.e. IC50 values) were then calculated [12].  
Statistical analysis 
All the data were run in triplicate for each sample. All data 
were expressed as mean ± standard deviation (SD)for  n  = 3. 
Student’s t-test analysis was done to assess the statistical 
significance of the data sets. A p value less than 0.05 was 
considered to indicate statistical significance for all 
comparisons. 
RESULTS AND DISCUSSION 
Selection of Wavelength for Simultaneous Estimation of 
x and y:  
Derivative Method: First order derivative spectrum for PTX 
showed zero crossing points: 249.9 nm. The wavelength 
selected for estimation of PTX was 249.9 nm because it 
showed adequate absorbance at this wavelength in mixture. 
Similarly, first order derivative spectrum for EMB was taken 
and it showed zero crossing point: 300 nm. The wavelength 
selected for estimation of EMB was 300 nm because it 
showed adequate absorbance at this wavelength in mixture.  
Table 1: Analytical data from the calibration graphs for 





ZCP (nm) 249.9 300 
Linearity range 5-21 μg/mL 3-11 μg/mL 
Regression equation a 0.0371x + 
0.0066 
0.07x - 0.034 
r2 0.998 0.999 
Absorbance 0.158 0.234 
LOD 0.03522 0.0187 
LOQ 0.10567 0.0566 
a absorbance value (A) versus concentration (C) of each 
drug in μg/mL 
Linerity: The assay showed a good linear response over the 
range 5-21 μg/mL for PTX and 3-11 μg/mL for EMB. The 
regression equations (n = 5) were y = 0.0371x + 0.0066 (r2 = 
0.998) for PTX and y = 0.0844x + 0.043 (r2 = 0.999) for EMB, 
where y is the peak area ratio of analyte to drug (PTX or 
EMB) and x is the methanolic PBS (7.4) concentration. At 
calibration curve concentrations, the RSD value ranged from 
0.19% to 0.93% for PTX and 0.83% to 1.10% for EMB. 
Analytical data from the calibration graphs for the 
determination of PTX-EMB by spectrophotometry is 
mentioned in table 1. 
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The developed method was novel, simple, accurate, and 
precise, economical, which would be used to estimate PTX 
and EMB in their combined dosage form in routine analysis. 
Hot homogenization method was used to prepare PTX-EMB 
loaded PEGylated SLNs. Optimization of process and 
formulation parameters results in the successfully 
production of PTX-EMB loaded PEGylated SLNs with particle 
size 316.3 ± 15.7 with PDI 0.075 ± 0.08 while that of SLNs 
without drug incorporation have particle size 137.3 ± 6.7 nm. 
However, the PTX-EMB loaded PEGylated SLNs remained 
within the injectable range for intravenous administration 
(~200–400 nm) [13]. The PEGylated phospholipid (DSPE-
PEG2000) is usual to provide additional steric stabilization 
of SLNs. Consequently, the prepared PEGylated SLNs in this 
study should theoretically stable for long periods and having 
long circulation time. Ultimately, TEM (transmission electron 
microscope) was used to inspect the morphology and 
submicron particle size of PEGylated SLNs (Figure 2). TEM 
studies show that particle size of PTX-EMB loaded PEGylated 
SLNs was found to be 300nm. 
Entrapment efficiency of drugs in the SLNs is 92.83 and 
83.25 for PTX and EMB respectively. 
 
 
Figure 2 TEM photograph of PTX and EMB loaded PEGylated SLNs 
 
Physical stability  
Physical stability of PTX-EMB loaded PEGylated SLNs was 
measured by investigating the changes in mean particle size 
for the duration of 30 days at 4°C and 25°C. Particle size 
values obtained at different days at both temperatures are 
shown in Figure 3. 
 
 
Figure 3: Stability study of PTX-EMB loaded PEGylated SLNs at 4°C and 25°C. Data presented as Mean ±SEM, n =3 
 
In-vitro drug release 
The in-vitro drug release study of the PTX-EMB loaded 
PEGylated SLNs was done in Methanolic PBS pH 7.4 using 
dialysis bag. The release study of the formulation was done 
thrice to check the reproducibility. Figure 4 shows the 
release of PTX and EMB from SLNs. 
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Figure 4: Percentage cumulative release of PTX and EMB vs. Time curve. Data presented as Mean ±SEM, n =3 
 
It is shown in the results that more than 50% of the total 
PTX was released in 40 hours while EMB in 56 hrs. This data 
further proves that there is sustain release of drug from the 
SLNs. Kinetics of drug release from controlled release 
formulation was evaluated by model dependent methods. 
PTX and EMB both drugs followed zero order kinetics. It 
shows that release of both was not depends upon time and 
concentration, release of both drugs follows the diffusion. 
Various kinetic models for PTX and EMB release from PTX-
EMB loaded PEGylated SLNs are given in Figure 5 and Figure 
6 respectively and in Table 2, regression value of PTX and 
EMB in various kinetic models of release study are given.
  
 
Figure 5: Kinetic models for PTX release from PTX-EMB loaded PEGylated SLNs 
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Figure 6: Kinetic models for EMB release from PTX-EMB loaded PEGylated SLNs 
 
The release kinetics of drug from SLNs can be described 
using four different kinetic models, which are Zero order, 
First order, Peppas model and Higuchi model. All of these 
models explain the release pattern to be dependent on some 
individual property. The mechanism of drug release was 
studied using zero order equation. 
Qt = Q0 + K0t 
Where Qt is cumulative amount of drug release at time t, Q0 
initial amount of drug, K0 is a zero-order release constant 
and t is the time. 
Table 2: Regression value of PTX and EMB in various 
kinetic models of release study 
Kinetic Models Regression(R2) 
Value of PTX 
Regression(R2) 
Value of EMB 
Zero Order Release 0.9362 0.9523 
First Order 0.8563 0.9397 
Peppas Model 0.8899 0.9084 
Higuchi Model 0.9328 0.9356 
 
In-vitro cell line study 
Cell Uptake Study: Cell uptake study of the formulation was 
performed for qualitative estimation of the uptake of SLNs by 
the cancer cells. Images of the cells were taken after 2 hours 
of incubation with the suspension of plain Coumarin-6, 
Coumarin-6 loaded SLNs and Coumarin-6 loaded PEGylated 
SLNs on Olympus CKX41 fluorescence microscope. We were 
able to see the fluorescence on B excitation filter of the 
microscope and the images were taken at 20 X magnification. 
Fluorescence in the cells can be clearly seen in the Figure 7, 
which shows that coumarin-6 loaded SLNs were taken up by 
the cells. Coumarin-6 loaded PEGylated SLNs (D) shows 
better uptake as compared to plain Coumarin-6 (B) and 
Coumarin-6 loaded SLNs (C). SLNs formulation travels inside 
the cells via mechanism of passive transport and so increase 
bioavailability of drug. PEGylation SLNs Inhibit the RES 
uptake of cells and make more effective the formulation.
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Figure 7: Images of cell uptake (A) Plain MCF-7 cells (B) Plain Coumarin-6 treated cells (C) Coumarin-6 loaded SLNs 
treated cells (D) Coumarin-6 loaded PEGylated SLNs treated cells 
 
Apoptosis Assay: Apoptosis study of optimized formulation 
PTX-EMB loaded PEGylated SLNs was conducted using 
Annexin V-FITC detection kit in MCF-7 cell lines, shown in 
Figure 8. In MCF-7 cells, control group (A) shows negligible 
presence of apoptosis and necrotic cells (less than 5%). The 
percentage of apoptotic cells was higher in case of cells 
treated with PTX-EMB loaded PEGylated SLNs (D) than PTX 
loaded PEGylated SLNs (C). With plain PTX treatment (B), 
we observed very few cells at pro-apoptotic phase as 
compared to PTX-EMB loaded PEGylated SLNs (D) and PTX 
loaded PEGylated SLNs (C). All formulations showed 
negligible amount of necrotic cells, while control group 
showed negligible apoptotic activity. 
  
 
Figure 8: Images of Apoptosis Assay (A) Plain MCF-7 cells (B) Plain PTX treated cells (C) PTX loaded PEGylated SLNs 
treated cells (D) PTX-EMB loaded PEGylated SLNs treated cells 
 
Optimized PTX-EMB loaded PEGylated SLNs (D) was able to 
cause a significant increase in programmed cell death. PTX 
loaded PEGylated SLNs (C) also cause a significant increase 
in programmed cell death as compare to plain PTX (B). But 
in combination with EMB i.e. PTX-EMB loaded PEGylated 
SLNs (D) showed better results because EMB serves to be 
apoptotic inducer and hence in synergism with PTX shows 
enhanced effect and better apoptosis. 
Cell viability by MTT assay: Cytotoxic curve and IC50 value 
were determined for different SLNs formulations (PTX 
loaded PEGylated SLNs and PTX-EMB loaded PEGylated 
SLNs) and further compared with PTX solution and PTX-
EMB mixture solution in dose dependent manner in MCF-7 
cell line using MTT assay. IC50 value, concentration of drug 
required for 50% cell death listed in table 3. 
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Table 3: IC50 values of PTX solution, PTX-EMB mixture 
solution, PTX loaded PEGylated SLNs and PTX-EMB 
loaded PEGylated SLNs. 
Formulation IC50 Value 
PTX solution 12 μg/ml 
PTX-EMB mixture solution 10 μg/ml 
PTX loaded PEGylated SLNs 9.4 μg/ml 
PTX-EMB loaded PEGylated SLNs 6 μg/ml 
 
From result it is observed that PTX-EMB loaded PEGylated 
SLNs exhibited significantly higher cytotoxicity as compared 
to PTX solution, PTX-EMB mixture solution and PTX loaded 
PEGylated SLNs at all drug concentration. IC50 value for MCF-
7 cells treated with PTX-EMB loaded PEGylated SLNs was 
found to be 6 μg/ml that was less than from PTX solution (12 
μg/ml), PTX-EMB mixture solution (10 μg/ml) and PTX 
loaded PEGylated SLNs (9.4 μg/ml). 
Therapeutic efficacy of drug loaded SLNs depends on cellular 
uptake, intracellular distribution and more importantly the 
amount of drug available from the internalized SLNs inside 
the cell [14]. The enhanced cytotoxicity effect of PTX-EMB 
loaded PEGylated SLNs could be attributed by higher uptake 
due to PEGylation of SLNs (Table 4, Figure 9). 
 
Table 4: Cytotoxicity study of PTX solution, PTX-EMB mixture solution, PTX loaded PEGylated SLNs and PTX-EMB 
loaded PEGylated SLNs in MCF-7 using MTT assay. 






% Cell Viability 
0 99.3 97.86 99.03 97.8 
2 97.61 91.25 89.09 74.5 
4 88.28 83.43 76.71 65.17 
6 75.42 71.5 64.33 53.51 
8 64.66 60.27 55.64 45.54 
10 56.46 49.76 47.54 39.22 
12 48.56 36.68 34.25 30.96 
 
 
Figure 9: Cytotoxicity study of PTX solution, PTX-EMB mixture solution, PTX loaded PEGylated SLNs and PTX-EMB 
loaded PEGylated SLNs in MCF-7 cell line using MTT assay. Data presented as Mean ± SEM, n =3 
 
This is because both the cytotoxic agents synergistically 
produced enhanced cytotoxicity. But interestingly, 
cytotoxicity of PTX- EMB loaded SLNs was found to be much 
higher than the physical mixture of the PTX-EMB. This 
proves that through drug loaded SLNs, drug is better uptake 
to and retained in the cancerous cells. These results indicate 
that PTX and EMB loading PEGylated SLNs is a novel and 
effective approach towards breast cancer management of 
the highly toxic chemotherapeutic drugs and thus producing 
fewer side effects. 
CONCLUSION 
From above studies, it has been concluded that the aim of 
the project has been achieved by developing the Paclitaxel 
and Embelin loaded PEGylated SLNs. The formulation 
showed good potential ability towards breast cancer. Also it 
was concluded that embelin played a significant role in up-
regulation of the TNFα induced apoptosis of paclitaxel. The 
optimized formulation (Paclitaxel and Embelin loaded 
PEGylated SLNs) exerts synergistic anti cancer activity 
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because of anti cancer properties of both paclitaxel and 
embelin. 
From the study we conclude that the formulation is effective 
and can be recommended for pre-clinical studies. 
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